60 -10 (60) 2023 — Isirgapova S.N., Sabirov M.A. — EFFECT OF ELECTROLYTE DISTURBANCES IN THE BLOOD ON QUALITY OF LIFE IN PATIENTS OF CLIMACTERIC PERIODCHKD IN 5 STAGE

EFFECT OF ELECTROLYTE DISTURBANCES IN THE BLOOD ON QUALITY OF LIFE IN PATIENTS OF CLIMACTERIC PERIODCHKD IN 5 STAGE

Isirgapova S.N., Tashkent State Dental Institute Uzbekistan

Sabirov M.A., Republican Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Sultonov N.N., Republican Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Maksudova L.I. Tashkent Pediatric Medical Institute

Resume

In menopausal patients at stage 5 of chronic kidney disease (CKD), disorders such as vasomotor symptoms, sleep disorders, decreased resistance to stress, changes in the genitourinary system, osteoporosis and hypomagnesemia are manifested, which are observed due to hormonal changes in women of menopausal age. All of the above factors can aggravate the menopausal period in women. Magnesium and hormone replacement therapy are used to treat these changes and improve women’s quality of life. The use of hormone therapy during menopause (HRT) plays an important role in the treatment of symptoms of the disease associated with estrogen deficiency. In patients with CKD of the 5th stage of the menopausal period, the existing deterioration in the quality of life is considered one of the main problems of modern medicine.

Keywords: Chronic kidney disease, menopausal period, hormonal changes, substitution therapy.

First page

354

Last page

361

For citation: Isirgapova S.N., Sabirov M.A., Sultonov N.N., Maksudova L.I. – EFFECT OF ELECTROLYTE DISTURBANCES IN THE BLOOD ON QUALITY OF LIFE IN PATIENTS OF CLIMACTERIC PERIODCHKD IN 5 STAGE //New Day in Medicine 2023 10(60): 354-361 https://newdaymedicine.com/index.php/2023/10/10/l-448/

LIST OF REFERENCES:

1. Амбрамова Е.Э., Королева И.Е., Тов Н.Л. и др. Факторы риска летальных исходов у больных на гемодиализе // Journal of Siberian Medical Sciences 2015;6:15-26.
2. Е.В. Брюхина, О.В. Иванова, Е.Н. Усольцева. Пcихометрические свойства русскоязычной версии опросника женского здоровья Women’s Health Questionnaire (WHQ). Вестник ЮУрГУ, 2012;42:134-142.
3. Сухих Г.Т., Сметник В.П. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации: протоколы // Климактерий. 2015;49.
4. Трисветова Е.Л. Магний и пиридоксин – две составляющие здоровья женщины. Белорусский государственный медицинский университет, Минск. // Медицинские новости. 2017;11:29-33.
5. Зайдиева Я.З. Альтернативная терапия менопаузальных расстройств у женщин в климактерии. // Акушерство/Гинекология. РМЖ, 2017;12:873-878.
6. Acta medica Eurasica. 2018. №1. Page 22-29.
7. Baber R.J., Panay N., Fenton A. et al. IMS Recommendations on women’s midlife health and menopause hormone therapy (MHT) // Climacteric. 2016;19(2):109–150.
8. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors / M.G. Shlipak // JAMA – 2015;293(14):1737 – 1745.
9. Guidelines for hormone treatment of women in the menopausal transition and beyond / F. Naftolin, H.P. Schneider, I.D. Sturdee et al. // Position state-ment by the Executive Committee of the International Menopause Society. 2005;127(3–4):94–96.
10. Mehta R.L, Cerdá J, Burdmann E.A, et al. International Society of Nephrology’s by 25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;27(385/9987):2616–43.